Treating Multibacillary Leprosy with the Alternative 8-Week Bedaquiline Monotherapy Regimen
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 17th, 2025
|
Multibacillary leprosy is a severe skin infection caused by Mycobacterium leprae that is typically treated with a 12-month course of clofazimine, dapsone, and rifampin. While this antimicrobial regimen is effective, it is challenging due to the adverse effects of dapsone, poor adherence resulting from the long treatment duration, and the emergence of resistant strains. Bedaquiline, a diarylquinoline that inhibits mycobacterial ATP synthase, offers a potential alternative to the current regimen. A study sponsored by Janssen was conducted to explore the use of bedaquiline monotherapy as a treatment for multibacillary leprosy.
The proof-of-concept study was conducted in Brazil with 11 participants diagnosed with multibacillary leprosy, each having at least 6 lesions. The study used an open-label design, where all participants began with a daily oral dose of 200 mg of bedaquiline for 2 weeks, followed by a reduction to 100 mg three times a week for the next 6 weeks. Participants were excluded from using other antimycobacterial agents, systemic antibiotics, HMG-CoA reductase inhibitors, hepatotoxic drugs, or medications that could cause arrhythmias. To evaluate antimycobacterial activity, skin biopsy punch samples were analyzed using culture and RT-qPCR. The researchers found that bedaquiline effectively eliminated Mycobacterium leprae after 4 weeks of treatment. Additionally, all participants showed significant improvement in skin lesions by the 7th week. In addition to its clinical efficacy, bedaquiline was associated with minimal adverse effects. The authors concluded that these promising results support the need for further research with a larger group of participants.
The proof-of-concept study was conducted in Brazil with 11 participants diagnosed with multibacillary leprosy, each having at least 6 lesions. The study used an open-label design, where all participants began with a daily oral dose of 200 mg of bedaquiline for 2 weeks, followed by a reduction to 100 mg three times a week for the next 6 weeks. Participants were excluded from using other antimycobacterial agents, systemic antibiotics, HMG-CoA reductase inhibitors, hepatotoxic drugs, or medications that could cause arrhythmias. To evaluate antimycobacterial activity, skin biopsy punch samples were analyzed using culture and RT-qPCR. The researchers found that bedaquiline effectively eliminated Mycobacterium leprae after 4 weeks of treatment. Additionally, all participants showed significant improvement in skin lesions by the 7th week. In addition to its clinical efficacy, bedaquiline was associated with minimal adverse effects. The authors concluded that these promising results support the need for further research with a larger group of participants.